Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 233-241

  Moss, Adam M ^a   Harris, Alon ^a   Siesky, Brent ^a   Rusia, Deepam ^a   Williamson, Kathleen M ^a   Shoshani, Yochai ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbonic anhydrase inhibitor; Glaucoma; Ocular blood flow; Optic nerve head; Timolol; Visual function

Indexed keywords

ACETAZOLAMIDE; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRINZOLAMIDE; BRINZOLAMIDE PLUS TIMOLOL; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; PILOCARPINE; TIMOLOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; EYE BLOOD FLOW; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; OPEN ANGLE GLAUCOMA; OPTIC NERVE; PULSATILE FLOW; REVIEW; RISK FACTOR; SCANNING LASER OPHTHALMOSCOPY; VISION;

EID: 77953380786     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: None     Document Type: Review

References (90)

1. Coleman AL, Kodjebacheva G. Risk factors for glaucoma needing more attention. Open Ophthalmol J. 2009;17:38-42.
2. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
3. Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999;106: 2144-2153.
4. Heijl A, Leske MC, Bengtsson B, et al; Early Manifest Glaucoma Trial Study Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
5. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498-505.
6. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology. 1998;105:1146-1164.
7. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130: 429-440.
8. Musch D, Gillespie B, Lichter P, et al. Visual field progression in the Collaborative Initial Glaucoma Treatment Study: The impact of treatment and other baseline factors. Ophthalmology. 2009;116: 200-207.
9. Chung HS, Harris A, Kagemann L, et al. Peripapillary retinal blood flow in normal tension glaucoma. Br J Ophthalmol. 1999;83:466-469.
10. Yin ZQ, Millar TJ, et al. Widespread choroidal insufficiency in primary open-angle glaucoma. J Glaucoma. 1997;6:23-32.
11. Butt Z, McKillop G, O'Brien C, et al. Measurement of ocular blood flow velocity using colour Doppler imaging in low tension glaucoma. Eye. 1995;9:29-33.
12. Galassi F, Sodi A, Ucci F, et al. Ocular hemodynamics in glaucoma associated with high myopia. Int Ophthalmol. 1998;22:299-305.
13. Harris A, Sergott RC, Spaeth GL, et al. Color Doppler analysis of ocular vessel blood velocity in normal-tension glaucoma. Am J Ophthalmol. 1994;118:642-649.
14. Rojanapongpun P, Drance SM, Morrison BJ. Ophthalmic artery flow velocity in glaucomatous and normal subjects. Br J Ophthalmol. 1993;77:25-29.
15. Weinreb RN, Harris A, editors. Ocular Blood Flow in Glaucoma: The 6th Consensus Report of the World Glaucoma Association. Section II: Clinical Measurement of Ocular Blood Flow. Kugler Publications: Amsterdam, The Netherlands; 2009:59.
16. Tielsch JM, Katz J, Sommer A, et al. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population based assessment. Arch Ophthalmol. 1995;113:216-221.
17. Leske MC, Connell AM, Wu SY, et al. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol. 1995;113: 918-924.
18. Bonomi L, Marchini G, Marraffa M, et al. Vascular risk factors for primary open-angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000;107:1287-1293.
19. Harris A, Jonescu-Cuypers C, Martin B, et al. Simultaneous management of blood flow and IOP in glaucoma. Acta Ophthalmol Scanda. 2001;79:336-341.
20. Nies AS, Evans GH, Shand DG. Regional hemodynamic effects of beta-adrenergic blockade with propanolol in the unanesthetized primate. Am Heart J. 1973;85:97-102.
21. Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J. 1980;100:160-178.
22. McSorley PD, Warren, DJ. Effects of propranolol and metoprolol on the peripheral circulation. Br Med J. 1978;2:1598-1600.
23. Elena PP, Kosina-Boix M, Moulin G, and Lapalus P. Autoradiographic localization of beta-adrenergic receptors in rabbit eye. Invest Ophthalmol Vis Sci. 1987;28:1436-1441.
24. Dawidek GMB, Robinson MI. Betaadrenergic receptors in human anterior optic nerve: an autoradiographic study. Eye. 1993;7:122-126.
25. Harris A, Martin B. Beta-blockers and ocular blood flow: a perspective. J Glaucoma. 1997;6:143-145.
26. Arend O, Harris A, Arend S, et al. The acute effect of topical beta-adrenoreceptor blocking agents on retinal and optic nerve head circulation. Acta Ophthalmol Scand. 1998;76:43-49.
27. Evans DW, Harris A, Chung HS, et al. Effects of long term hypotension therapy with nonselective beta-blockers on ocular hemodynamics in primary open-angle glaucoma. J Glaucoma. 1999;8(1):12-17.
28. Netland PA, Schwartz B, Feke GT, Takamoto T, Konno S, Goger DG. Diversity of response of optic nerve head circulation to timolol maleate in gel-forming solution. J Glaucoma. 1999;8:164-171.
29. Fuchsjager-Mayrl G, Wally B, Rainer G, Buehl W, Aggermann T, Kolodjaschna J, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2005;89:1293-1297.
30. Tamaki Y, Araie M, Tomita K, Nagahara M, Tomidokoro A. Effect of topical beta-blockers on tissue blood flow in the human optic nerve head. Curr Eye Res. 1997;16:1102-1110.
31. Evans DW, Harris A, Chung HS, Cantor LB, Garzozi HJ. Effects of long-term hypotensive therapy with nonselective beta-blockers on ocular hemodynamics in primary open-angle glaucoma. J Glaucoma. 1999;8:12-17.
32. Galassi F, Sodi A, Renieri G, Ucci F, Pieri B, Harris A, et al. Effects of timolol and dorzolamide on retrobulbar hemodynamics in patients with newly diagnosed primary open-angle glaucoma. Ophthalmologica. 2002;216:123-128.
33. Harris A, Spaeth GL, Sergott RC, Katz LJ, Cantor LB, Martin BJ. Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma. Am J Ophthalmol. 1995;120:168-175.
34. Arend O, Harris A, Wolter P, Remky A. Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly diagnosed open-angle glaucoma patients. Acta Ophthalmol Scand. 2003;81:474-479.
35. Laux BE, Raichle ME. The effect of acetazolamide on cerebral bloow flow and oxygen utilization in the rhesus monkey. J Clin Invest. 1978;62:585-592.
36. Stanescu B, Michiels J. The effects of acetazolamide on the human electroretinogram. Invest Ophthalmol. 1975;14:935-937.
37. Siesky B, Harris A, Brizendine E, et al. Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv Ophthalmol. 2009;54:33-46.
38. Lichter P, Musch D, Gillespie B, et al. Interim clinical outcomes in the Collaborative Initail Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953.
39. Clineschmidt CM, William RD, Snyder E, et al. A randonmized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology. 1998;105:1952-1959.
40. Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol. 1998;82:1249-1253.
41. Kaback M, Scoper S, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008;115:1728-1734.
42. Weinreb RN, Harris A, ed. Ocular Blood Flow in Glaucoma: The 6th consensus report of the World Glaucoma Association. Section III: Clinical Relevance of Ocular Blood Flow Measurements including Effects of General Medications or A Specific Glaucoma Treatment. Kugler Publications: Amsterdam, The Netherlands; 2009:60.
43. Surgue M. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000;19:87-112.
44. Januleviciene I, Harris A, Kagemann L, et al. A comparison of the effects of dorzolamide/timolol fixed combination versus latano- prost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta Ophthalmol Scand. 2004;82:730-737.
45. Manni G, Centofanti M, Gregori D, et al. The pulsatile ocular blood flow behaviour in open angle glaucoma patients after replacing timolol therapy with timolol and dorzolamide fixed combination: preliminary study. Acta Ophthalmol Scand. 2002;236(Suppl):55-56.
46. Schmidt KG, von Ruckmann A, Becker R, et al. Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma. Klin Monatsbl Augenheilkd. 1999;215:361-366.
47. Weizer JS, Asrani S, Stinnett SS, et al. The clinical utility of dynamic contour tonometry and ocular pulse amplitude. J Glaucoma. 2007;16:700-703.
48. Yang Y, Hulbert M, Batterbury M, et al. Pulsatile ocular blood flow measurements in healthy eyes: reproducibility and reference values. J Glaucoma. 1997;6:175-179.
49. Weinreb RN, Harris A, editors. Ocular Blood Flow in Glaucoma: The 6th consensus report of the World Glaucoma Association. Section II: Clinical Measurement of Ocular Blood Flow. Kugler Publications: Amsterdam, The Netherlands; 2009:21-22.
50. Siesky B, Harris A, Sines D, et al. A comparative analysis of the effects of the fixed combination of timolol and dorzolamide versus latanoprost plus timolol on ocular hemodynamics and visual function in patients with primary open-angle glaucoma. J Ocul Pharmacol Ther. 2006;22:353-361.
51. Spencer JA, Giussani DA, Moore PJ, Hanson MA, et al. In vitro validation of Doppler indices using blood and water. J Ultrasound Med. 1991;10:305-308.
52. Orge F, Harris A, Kagemann L, et al. The first technique for noninvasive measurements for volumetric ophthalmic artery blood flow in humans. Br J Ophthalmol. 2002;86:1216-1219.
53. Uva MG, Longo A, Reibaldi M, et al. The effect of timololdorzolamide and timolol-pilocarpine combinations on ocular blood flow in patients with glaucoma. Am J Ophthalmol. 2006;141:1158-1160.
54. Martinez A, Sanchez M. A comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patients. Curr Med Res Opin. 2006;22:67-73.
55. Martinez A, Sanchez M. Retrobulbar haemodynamic effects of the latanoprost/timolol and the dorzolamide/timolol fixed combinations in newly diagnosed glaucoma patients. Int J Clin Pract. 2007;61: 815-825.
56. Martinez A, Sanchez-Salorio M. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. J Ocul Pharm. 2009;25:239-248.
57. Stams T, Chen Y, Boriack-Sjodin PA, et al. Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isoenzyme-drug discrimination. Protein Sci. 1998;7:556-563.
58. Harris A, Williamson TH, Martin B, et al. Test/Retest reproducibility of color Doppler imaging assessment of blood flow in orbital vessels. J Glaucoma. 1995;4:281-286.
59. Stalmans I, Siesky B, Zeyen T, et al. Reproducibilty of color Doppler imaging. Graefes Arch Clin Exp Ophthalmol. 2009;247:1531-1.
60. Quaranta L, Harris A, Donato F, et al. Color Doppler imaging of ophthalmic artery blood flow velocity: a study of repeatability and agreement. Ophthalmology. 1997;104:653-658.
61. Harris A, Arend O, Chung HS, et al. A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients. Ophthalmology. 2000;107:430-434.
62. Chung H, Harris, Halter P, et al. Regional differences in retinal vascular reactivity. Invest Ophthalmol Vis Sci. 1999;2448-2453.
63. Harris A, Jonescu-Cuypers CP, Kagemann L, et al. Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma. Am J Ophthalmol. 2001;132: 490-495.
64. Weinreb R, Harris A, editors. Ocular Blood Flow in Glaucoma: The 6th consensus report of the World Glaucoma Association. Section II: Clinical Measurement of Ocular Blood Flow. Kugler Publications: Amsterdam, The Netherlands; 2009:35-38.
65. Harris A, Arend O, Arend S, et al. Effects of topical dorzolamide on retinal and retrobulbar hemodynamics. Acta Ophthalmol Scand. 1996;74:569-572.
66. Ehrenreich DL, Burns RA, Alman RW, et al. Influence of acetazolamide on cerebral blood flow. Arch Neurol. 1961;5:125-130.
67. Rassam SM, Patel V, Kohner EM. The effect of acetazolamide on the retinal circulation. Eye. 1993;7:697-702.
68. Taki K, Kato H, Endo S, et al. Cascade of acetazolamide-induced vasodilatation. Res Commun Mol Pathol Pharmacol. 1999;43:386-391.
69. Stanescu B, Michiels J. The effects of acetazolamide on the human electroretinogram. Invest Ophthalmol. 1975;14:935-937.
70. Pedersen DB, Stefánsson E, Kiilgaard JF, et al. Optic nerve pH and PO2: the effects of carbonic anhydrase inhibition, and metabolic and respiratory acidosis. Acta Ophthalmol Scand.
71. Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmol. 2008;115: 1728-1734.
72. Weinreb R, Harris A, editors. Ocular Blood Flow in Glaucoma: The 6th consensus report of the World Glaucoma Association. Section V: What Do We Still Need to Know? Kugler Publications: Amsterdam, The Netherlands; 2009:143-153.
73. Plange N, Kaup M, Arend O, et al. Asymmetric visual field loss and retrobulbar haemodynamics in primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2006;244;978-983.
74. Zeitz O, Galambos P, Wagenfeld L, et al. Glaucoma progression is associated with decreased blood flow velocities in the short posterior ciliary artery. Br J Ophthalmol. 2006;90;1245-1248.
75. Galassi F, Sodi A, Ucci F, et al. Ocular hemodynamics and glaucoma prognosis: a color Doppler imaging study. Arch Ophthalmol. 2003;121;1711-1715.
76. Martinez A, Sanchez M. Predictive value of colour Doppler imaging in a prospective study of visual field progression in primary open angle glaucoma. Acta Ophthalmol Scand. 2005;83;716-722.
77. Satilmis M, Orgul S, Doubler B, et al. Rate of progression of glaucoma correlates with retrobulbar circulation and intraocular pressure. Am J Ophthalmol. 2003;135:664-669.
78. Lam A, Piltz-Seymour J, Dupont J, et al. Laser Doppler flowmetry in asymmetric glaucoma. Curr Eye Res. 2005;30:221-227.
79. Sato EA, Ohtake Y, Shinoda K, et al. Decreased blood flow at neuroretinal rim of optic nerve corresponds with visual field deficit in eyes with normal tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 2006;244:795-801.
80. Sato EA, Shinoda K, Inoue M, et al. Reduced choroidal blood flow can induce visual field defect in open angle glaucoma patients without intraocular pressure elevation following sclera buckling. Retina. 2008;28:493-497.
81. Kozobolis VP, Detorakis ET, Georgiadis GS, et al. Perimetric and retrobulbar blood flow changes following carotid endarterectomy. Graefes Arch Clin Exp Ophthalmol. 2007;245:1639-1645.
82. Martinez A, Sanchez M. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study. Clin Ther. 2008;30;1120-1134.
83. The European Glaucoma Prevention Study (EGPS) Group. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005;112:366-375.
84. Arend O, Harris A, Wolter P, et al. Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly diagnosed open-angle glaucoma patients. Acta Ophthalmol Scand. 2003;81:47-49.
85. Arend O, Remky A, Cantor LB, et al. Altitudinal visual field asymmetry is coupled with altered retinal circulation in patients with normal pressure glaucoma. Br J Ophthalmol. 2000;84:1008-1012.
86. Martinez A, Sanchez-Salorio. Predictors for visual field progression and effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma. Acta Ophthalmologica. 2009; DOI:10.111/j/1755-3768.2009.01595.x [Epub ahead of print].
87. Logan JF, Rankin SJ, Jackson AJ, et al. Retinal blood flow measurements and neuroretinal rim damage in glaucoma. Br J Ophthalmol. 2004;88:1049-1054.
88. Hafez AS, Bizzarro RL, Lesk MR. Evaluation of optic nerve head and peripapillary retinal blood flow in glaucoma patients, ocular hypertensives, and normal subjects. Am J Ophthalmol. 2003;136:1022-1031.
89. Januleviciene I, Sliesoraityte I, Sieky B, et al. Diagnostic compatibility of structural and hemodynamic parameters in open-angle glaucoma patients. Acta Ophthalmol. 2008;86:552-557.
90. Januleviciene I, Ehrlich R, Siesky B, et al. Visual Funcion, optic nerve structure, and ocular blood flow parameters after 1 year of glaucoma treatment with fixed combinations. Eur J Ophthalmol. 2009;19: 790-797.